Pharma stock engaged in the business of manufacturing and trading drugs pharmaceuticals, and healthcare products jumped 3 percent in the day’s trade upon signing an exclusive partnership agreement with Cipla Limited.
With a market capitalization of Rs. 18,254 Crores, the shares of Sanofi India Limited were trading at Rs. 7,922.55, up 2.75 percent from its previous day’s close price of Rs. 7,701.85.
Sanofi India Limited and Cipla Limited have signed an exclusive partnership agreement for the distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India
As per the terms of the partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category
Cipla will use its India-wide network of marketing and sales professionals, distributors, institutions, and market outreach programs to increase access to CNS treatments for patients in need. Sanofi India will continue to own, import, and manufacture its entire range of CNS products in India and abroad.
Sanofi India is primarily engaged in the business of manufacturing and trading drugs, pharmaceuticals, and healthcare products used across the treatment of diabetes, cardiology, allergies, infections, and many more.
It has reported a return on equity (ROE) of 51.5 percent and a return on capital employed (ROCE) of 71.1 percent, it is making good returns on its equity and capital employed.
Its revenue from operations grew by 3.27 percent from Rs. 672 Crores in Q3FY23 to Rs. 694 Crores in Q3FY24, accompanied by profits of Rs. 131 Crores to Rs. 138 Crores.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
